Premium
GSK‐3ß INHIBITOR, 9‐ING‐41 REDUCES CELL VIABILITY AND HALTS PROLIFERATION OF B‐CELL LYMPHOMA
Author(s) -
Karmali R.,
Chukkapalli V.,
Pro B.,
Borgia J.A.,
Mazar A.,
Ugolkov A.,
Giles F.J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_175
Subject(s) - viability assay , cell growth , protein kinase b , pi3k/akt/mtor pathway , cancer research , cyclin dependent kinase , cell culture , apoptosis , kinase , cdk inhibitor , chemistry , biology , cell cycle , medicine , microbiology and biotechnology , biochemistry , genetics